Merck presents results from chronic hepatitis C therapy trial
Merck has recently completed both of its Phase 2 clinical trials that test the effectiveness and safety of a new treatment that requires a once-daily regimen containing 100 mg of grazoprevir and 50mg of elbasvir. Combining grazoprevir and elbasvir with ribavirin (RBV) has resulted in high rates of increase virologic responses for 12 weeks after the treatment was administered. The test group involved patients who have chronic HCV genotype 1 infections. The subjects included patients with or without liver cirrhosis who failed previous data aggregation agent combination therapy.
“We continue to advance our Phase 3 clinical program for grazoprevir/elbasvir evaluating diverse patient populations with chronic HCV infection, including those widely considered among the most difficult to treat,” Eliav Barr, vice president of infectious disease research at Merck Research Laboratories, said. “Findings from these Phase 2 studies formed part of the basis for our decision to rapidly advance our large and comprehensive clinical development program that incorporates studies dedicated to patient populations with specific unmet medical needs.”